Dkk-1 Antibody (BHQ-880)
Novus Biologicals, part of Bio-Techne | Catalog # NBP3-28459
Recombinant Monoclonal Antibody
Conjugate
Catalog #
Key Product Details
Species Reactivity
Human
Applications
ELISA, Flow Cytometry, Functional
Label
Unconjugated
Antibody Source
Recombinant Monoclonal Human IgG1 Clone # BHQ-880
Concentration
LYOPH mg/ml
Product Specifications
Immunogen
DKK1
Clonality
Monoclonal
Host
Human
Isotype
IgG1
Endotoxin Level
< 0.001EU/ug,determined by LAL method.
Description
Expressed from CHO. It has a predicted MW of 145.5 kDa.
Upon receipt, store immediately at -20C or lower for 24 months in a lyophilized state. - 80C for 3 months after reconstitution. Avoid repeated freeze-thaw cycles.
Upon receipt, store immediately at -20C or lower for 24 months in a lyophilized state. - 80C for 3 months after reconstitution. Avoid repeated freeze-thaw cycles.
Applications for Dkk-1 Antibody (BHQ-880)
Application
Recommended Usage
ELISA
Optimal dilutions of this antibody should be experimentally determined.
Flow Cytometry
Optimal dilutions of this antibody should be experimentally determined.
Functional
Optimal dilutions of this antibody should be experimentally determined.
Formulation, Preparation, and Storage
Purification
Protein A purified
Reconstitution
Reconstitute with sterile, distilled water to a final concentration of 1 mg/ml. Gently shake to solubilize completely. Do not vortex.
Formulation
Lyophilized from 25mM histidine, 8% sucrose, 0.01% Tween80 (pH6.2)
Preservative
No Preservative
Concentration
LYOPH mg/ml
Shipping
The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4C.
Background: Dkk-1
Additional Dkk-1 Products
Product Documents for Dkk-1 Antibody (BHQ-880)
Product Specific Notices for Dkk-1 Antibody (BHQ-880)
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...